VR Logo

Jubilant Life Sciences: Licensing Agreement With Gilead For Remdesivir A Potential Therapy For Covid-19

Dear Sirs

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we enclose a communication pertaining to Licensing Agreement with
Gilead for remdesivir a potential therapy for Covid-19.

We request you to take the same on record.

Click here to view PDF